OBJECTIVE: To gain first evidence on the patient satisfaction after treatment with botulinum toxin type A (BTX-A) and to check for differences in satisfaction with respect to clinical, psychologic, and sociodemographic parameters. METHODS: In this pilot study, 30 patients who had been treated with BTX-A within the last 3 months answered a standardized questionnaire (the Freiburg questionnaire on aesthetic dermatology and cosmetic surgery). The items assessed were attitudes on beauty and body, satisfaction with treatment outcome, and general quality of life. A prospective study consisting of the same items runs parallel and will be published later. RESULTS: More than 80% of the patients answered that the treatment had been beneficial to them. All patients would recommend treatment completely or mostly. Only a very small part of the patients was moderately stressed by the treatment. CONCLUSION: Injections with BTX-A is a satisfying and well-tolerated treatment of dynamic facial lines for all patients in this pilot study.
OBJECTIVE: To gain first evidence on the patient satisfaction after treatment with botulinum toxin type A (BTX-A) and to check for differences in satisfaction with respect to clinical, psychologic, and sociodemographic parameters. METHODS: In this pilot study, 30 patients who had been treated with BTX-A within the last 3 months answered a standardized questionnaire (the Freiburg questionnaire on aesthetic dermatology and cosmetic surgery). The items assessed were attitudes on beauty and body, satisfaction with treatment outcome, and general quality of life. A prospective study consisting of the same items runs parallel and will be published later. RESULTS: More than 80% of the patients answered that the treatment had been beneficial to them. All patients would recommend treatment completely or mostly. Only a very small part of the patients was moderately stressed by the treatment. CONCLUSION: Injections with BTX-A is a satisfying and well-tolerated treatment of dynamic facial lines for all patients in this pilot study.
Authors: O P Kreyden; B Rzany; P Becker-Wegerich; C Boudny-Frey; P Carrozza-Merlani; M Hess-Schmid; B Schlagenhauff Journal: Hautarzt Date: 2015-02 Impact factor: 0.751
Authors: M Axel Wollmer; Nadeem Kalak; Stefanie Jung; Claas de Boer; Michelle Magid; Jason S Reichenberg; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger Journal: Front Psychiatry Date: 2014-03-31 Impact factor: 4.157